کیگتروپین نام تجاری انسان ساخته شده مصنوعی است,کیگتروپین بهترین سوماتروپین HGH در بازار است که مؤثرترین و بهترین نتایجی است که یک فرد می تواند به دست آورد, kigtropin مهندسی شده است. ما سفارش را از ایالات متحده ارسال می کنیم, چین, و اتحادیه اروپا. ما توزیع کننده هستیم?کیگتروپین HGH عمده فروش? کیگتروپین HGH, لطفا kigtropin HGH چین بیشتری دریافت کنید (سرزمین اصلی) تولید کنندگان, صادرکنندگان, تامین کنندگان, کارخانه ها, شرکت هایی از چین .
کیگتروپین یک هورمون رشد انسانی است (HGH) سوماتروپین تولید شده با فناوری DNA نوترکیب مشابه با بدن به طور طبیعی HGH تولید می کند.
نارسایی رشد کودکان به دلیل کمبود هورمون رشد درون زا (GHD).
در بزرگسالان مبتلا به کمبود هورمون رشد,کیگتروپین توده چربی را کاهش می دهد,توده عضلانی را افزایش می دهد و انرژی را افزایش می دهد,سرزندگی و رفاه ذهنی. در بیمارانی که از سوختگی شدید رنج می برند,تحلیل عضلانی مرتبط با ایدز,یا در حال انجام عملیات های بزرگ,KIGTROPIN باعث بهبود زخم می شود,پاسخ پروتئین کاتابولیک را کاهش می دهد و وضعیت نیتروژن کل بدن را پس از عمل بهبود می بخشد.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 میلی گرم) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 ماه ها. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 سال ها, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
